Business
Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days
The major milestone refers to Inspira's proprietary technology to oxygenate blood for the INSPIRA™ ART (Gen 2). This patented tech is considered by Inspira to
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"The major milestone refers to Inspira's proprietary technology to oxygenate blood for the INSPIRA™ ART (Gen 2). This patented tech is considered by Inspira to be a game-changer and also aims to replace technologies used today by current medical device companies.Anticipated U.S. Food and Drug Administration (FDA) Clearance for INSPIRA™ ART100 (Gen 1) in the first half of 2024, to address the $1.16 Billion perfusion systems market.RA'ANANA, Israel, March 4, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the \"Company\" or \"Inspira\"), a breakthrough medical technology company, announced today that the Company's President, and co-founder, Mr. Joe Hayon, presented key highlights included in the Company's Investor Presentation and announced the Company's next major milestone of a core blood oxygenation technology of the INSPIRA ART (Gen 2). The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA™ blood Sensor and VORTX™ Orbiting Blood Oxygenation, to delivery oxygen straight into the blood. The proprietary core technology has undergone a series of testing in a variety of settings, with the results being collected and analyzed. The results refer to the INSPIRA ART (Gen 2), with the new core technology potentially being suitable for replacing current solutions in medical markets dominated by leading medical device companies. The Company plans to announce the primary results around the core blood oxygenation technology of the INSPIRA ART (Gen 2) within days.\n\n \n \nMr. Hayon shared \"We have an appetite to revolutionize the huge life-support mechanical ventilation market. In addition, it's important to emphasize that we believe INSPIRA ART100 (Gen 1) itself addresses $1B market.\" Key highlights from the conference call included:\nThe current healthcare challenge and a personal story.The solution – Inspira's oxygen delivery straight into the blood.INSPIRA™ART (Gen 2), Adaptive Blood Oxygenation and expected major milestone.INSPIRA™ ART Gen 1 and Gen 2 product overview.Anticipated FDA Clearance for INSPIRA™ ART100 (Gen 1).Mr. Hayon shared a heartfelt personal story and the profound impact of Inspira beyond technological innovation. He recounted his father's prolonged reliance on mechanical ventilation, painting a vivid picture of the ch...